This clinical trial is for men age 18 and older with prostate cancer to check safety and tolerability of IMMU-132.
Prostate cancer is the most common cancer in men in United States, after skin cancer, with more than 3 million cases per year. Initial therapies of prostate cancer include either surgical or chemical castration followed by androgen-deprivation therapy. Metastatic castration-resistant prostate cancer (mCRPC) is the resolution of the androgen receptor (AR) that leads cancer proliferation, tumor invasion and metastasis. There is no standard of care for mCRPC and efficacy of androgen receptor modulators and chemotherapy is moderate. Therefore, there is a need to find more effective treatments with fewer side effects.
IMMU-132 is an antibody drug that stimulates the immune system and may stop cancer cells from growing.
This study is a single-arm study. Patients will take the medication to intravenous injection (IV) for a 21-day cycle. All patients will be followed for survival until end of study or until sponsor ends the study. They will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.